Genprex – FDA Grants Fast Track Approval For Promising New Cancer Gene Therapy

Rodney Varner, CEO, Chairman & President of Genprex, Inc. GNPX, was recently a guest on Benzinga’s All-Access.

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. 

The company has recently received a new FDA Fast Track approval for its lead candidate, Reqorsa.

Watch the full interview here:

Featured photo by Hal Gatewood on Unsplash.

This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!